DWORF Peptide SERCA Pump Activator Heart Failure Treatment
Summary
The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.
What changed
The USPTO published patent application US20260098067A1 covering the DWORF peptide as a therapeutic agent for heart failure and calcium overload disorders. The application discloses compositions and methods for using this native peptide that enhances SERCA pump activity. The inventors include Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, and Benjamin R. Nelson.
Pharmaceutical and biotechnology companies developing cardiac therapies or calcium-handling modulators should monitor this application's progress through patent prosecution. Medical researchers studying heart failure treatments and SERCA pump biology may find relevant prior art considerations in this filing.
What to do next
- Monitor patent prosecution status for potential licensing opportunities
- Assess Freedom to Operate if developing competing cardiac therapies
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF A SMALL NATIVE PEPTIDE ACTIVATOR OF SERCA PUMP FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS CHARACTERIZED BY CYTOSOLIC CALCIUM OVERLOAD
Application US20260098067A1 Kind: A1 Apr 09, 2026
Assignee
The Board of Regents of The University of Texas System
Inventors
Eric N. OLSON, Rhonda S. BASSEL-DUBY, Catherine A. MAKAREWICH, Benjamin R. NELSON
Abstract
The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
CPC Classifications
C07K 14/47 A61K 38/1709 A61K 45/06 A61K 48/0058
Filing Date
2025-06-05
Application No.
19229899
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.